Barclays
AVNR

Barclays’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Barclays’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-65,900
Closed -$1.05M – 7543
2014
Q4 		$1.05M Sell
65,900
-12,800
-16% -$180K ﹤0.01% 3166
2014
Q3 		$866K Buy
78,700
+45,700
+138% +$312K ﹤0.01% 3486
2014
Q2 		$165K Buy
33,000
+27,700
+523% +$128K ﹤0.01% 4998
2014
Q1 		$16K Sell
5,300
-100
-2% -$381 ﹤0.01% 6725
2013
Q4 		$16K Sell
5,400
-6,600
-55% -$27.3K ﹤0.01% 6836
2013
Q3 		$48K Sell
12,000
-2,400
-17% -$11.4K ﹤0.01% 6086
2013
Q2 		$66K Buy
+14,400
New +$49.5K ﹤0.01% 6113

Barclays's AVNR Position: Q1 2015 in Review

Barclays sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 2,085,179 shares — an estimated $33.4M sold.

Barclays first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $33.4M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • Barclays reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • Barclays sold 2,085,179 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $33.4M.
  • Barclays first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
  • Barclays's AVANIR PHARMACEUTICALS, INC CL A position peaked at $33.4M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Barclays's 13F filing for Q1 2015, filed 14 May 2015.